Shares of diagnostics company Guardant Health (NASDAQ:GH)
jumped 5.2% in the morning session after the company announced a collaboration with Quest Diagnostics and provided an upbeat financial outlook at its investor day. The partnership aimed to make Guardant's Shield blood-based cancer screening test more widely available to physicians and patients in the United States. During its investor event, the company also revealed it accelerated its timeline for reaching cash flow breakeven by about 12 months.
Guardant Health’s 28.8% return over the past six months has outpaced the S&P 500 by 13.3%, and its stock price has climbed to $60.20 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Shares of diagnostics company Guardant Health (NASDAQ:GH)
jumped 1.2% in the afternoon session after multiple financial analysts issued positive ratings on the stock. Canaccord Genuity reaffirmed its "Buy" rating with a $65 price target ahead of the company's investor day.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q2, starting with Guardant Health (NASDAQ:GH).
Looking back on testing & diagnostics services stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Guardant Health (NASDAQ:GH) and its peers.
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.
Shares of diagnostics company Guardant Health (NASDAQ:GH)
fell 7.1% in the morning session after the company announced updated clinical results for its Shield blood-based colorectal cancer screening test.
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding.
Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
Diagnostics company Guardant Health (NASDAQ:GH) announced better-than-expected revenue in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company’s full-year revenue guidance of $920 million at the midpoint came in 3.9% above analysts’ estimates. Its non-GAAP loss of $0.44 per share was 14.5% above analysts’ consensus estimates.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential.
However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Diagnostics company Guardant Health (NASDAQ:GH) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company’s full-year revenue guidance of $920 million at the midpoint came in 3.9% above analysts’ estimates. Its non-GAAP loss of $0.44 per share was 14.5% above analysts’ consensus estimates.
